Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes
Articolo
Data di Pubblicazione:
2013
Citazione:
Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation
with outcomes / Metra, Marco; Cotter, G.; Davison, B. A.; Felker, G. M.; Filippatos, G.; Greenberg, B. H.; Ponikowski, P.; Unemori, E.; Voors, A. A.; Adams, K. F.; Dorobantu, M. I.; Grinfeld, L.; Jondeau, G.; Marmor, A.; Masip, J.; Pang, P. S.; Werdan, K.; Prescott, M. F.; Edwards, C.; Teichman, S. L; Trapani, A.; Bush, C. A.; Saini, R.; Schumacher, C.; Severin, T.; Teerlink, J. R.. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 1558-3597. - 61:2(2013), pp. 196-206. [10.1016/j.jacc.2012.11.005]
Abstract:
OBJECTIVES:
The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to 180-day mortality in patients with acute heart failure.
BACKGROUND:
Hospitalization for acute heart failure is associated with high post-discharge mortality, and this may be related to organ damage.
METHODS:
The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase III study were international, multicenter, double-blind, placebo-controlled trials in which patients hospitalized for acute heart failure were randomized within 16 h to intravenous placebo or serelaxin. Each patient was followed daily to day 5 or discharge and at days 5, 14, and 60 after enrollment. Vital status was assessed through 180 days. In RELAX-AHF, laboratory evaluations were performed daily to day 5 and at day 14. Plasma levels of biomarkers were measured at baseline and days 2, 5, and 14. All-cause mortality was assessed as a safety endpoint in both studies.
RESULTS:
Serelaxin reduced 180-day mortality, with similar effects in the phase II and phase III studies (combined studies: N = 1,395; hazard ratio: 0.62; 95% confidence interval: 0.43 to 0.88; p = 0.0076). In RELAX-AHF, changes in markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and alanine transaminase) damage and of decongestion (N-terminal pro-brain natriuretic peptide) at day 2 and worsening heart failure during admission were associated with 180-day mortality. Serelaxin administration improved these markers, consistent with the prevention of organ damage and faster decongestion.
CONCLUSIONS:
Early administration of serelaxin was associated with a reduction of 180-day mortality, and this occurred with fewer signs of organ damage and more rapid relief of congestion during the first days after admission.
The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to 180-day mortality in patients with acute heart failure.
BACKGROUND:
Hospitalization for acute heart failure is associated with high post-discharge mortality, and this may be related to organ damage.
METHODS:
The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase III study were international, multicenter, double-blind, placebo-controlled trials in which patients hospitalized for acute heart failure were randomized within 16 h to intravenous placebo or serelaxin. Each patient was followed daily to day 5 or discharge and at days 5, 14, and 60 after enrollment. Vital status was assessed through 180 days. In RELAX-AHF, laboratory evaluations were performed daily to day 5 and at day 14. Plasma levels of biomarkers were measured at baseline and days 2, 5, and 14. All-cause mortality was assessed as a safety endpoint in both studies.
RESULTS:
Serelaxin reduced 180-day mortality, with similar effects in the phase II and phase III studies (combined studies: N = 1,395; hazard ratio: 0.62; 95% confidence interval: 0.43 to 0.88; p = 0.0076). In RELAX-AHF, changes in markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate transaminase and alanine transaminase) damage and of decongestion (N-terminal pro-brain natriuretic peptide) at day 2 and worsening heart failure during admission were associated with 180-day mortality. Serelaxin administration improved these markers, consistent with the prevention of organ damage and faster decongestion.
CONCLUSIONS:
Early administration of serelaxin was associated with a reduction of 180-day mortality, and this occurred with fewer signs of organ damage and more rapid relief of congestion during the first days after admission.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
Heart failure; serelaxin; biomarkers
Elenco autori:
Metra, Marco; Cotter, G.; Davison, B. A.; Felker, G. M.; Filippatos, G.; Greenberg, B. H.; Ponikowski, P.; Unemori, E.; Voors, A. A.; Adams, K. F.; Dorobantu, M. I.; Grinfeld, L.; Jondeau, G.; Marmor, A.; Masip, J.; Pang, P. S.; Werdan, K.; Prescott, M. F.; Edwards, C.; Teichman, S. L; Trapani, A.; Bush, C. A.; Saini, R.; Schumacher, C.; Severin, T.; Teerlink, J. R.
Link alla scheda completa:
Pubblicato in: